source
- Human‑centric testing methods promise safer, cheaper drug development but repeatability remains a key obstacleRegulators such as the FDA, EMA and ICH are urging drug developers to replace animal safety studies with New Approach Methodologies that use human‑relevant models. Early research shows these models…
- AI drug hunter Enveda raises $311M for late-stage obesity, inflammatory disease pushTech darling Enveda has raised a total of $845 million in the past six years. The latest funding round is intended to pave the way for an IPO someday.